🏆 Finalist — NIH Data Sharing Index (“S-Index”) Challenge

Ana Verma

Boston University

ORCID: 0000-0001-9057-171X

Also affiliated with Brigham and Women's Hospital, Harvard University, Ludwig Cancer Research

Biochemistry, Genetics and Molecular BiologyMedicine

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 4 papers. Top paper: “Imlunestrant a next-generation oral SERD overcomes ESR1 mutant resistance in estrogen receptor–positive breast cancer”.

Imlunestrant a next-generation oral SERD overcomes ESR1 mutant resistance in estrogen receptor–positive breast cancer

JCI Insight(2025)10.1172/jci.insight.188051

N/A

0.385DataRank · unranked

12 citations

Zachary M. Sandusky, Douglas Russo, David Zak, Agostina Nardone, Delia Friel +11 more

Pure estrogen receptor antagonists potentiate capecitabine activity in ESR1-mutant breast cancer

npj Breast Cancer(2024)10.1038/s41523-024-00647-1

N/A

0.241DataRank · unranked

4 citations

Douglas Russo, Wen Ma, Ana Verma, Francisco Hermida-Prado, Shira Sherman +13 more

Targeting Pin1 renders pancreatic cancer eradicable by synergizing with immunochemotherapy

Cell(2021)10.1016/j.cell.2021.07.020

N/A

0DataRank · unranked

244 citations

Shin Kibe, Futoshi Suizu, Nobufumi Sekino, Nami Kim, Theresa Manz +22 more

Comparative effectiveness of antidiabetic therapies on hepatic decompensation in patients with type 2 diabetes: A target trial emulation

JHEP Reports(2025)10.1016/j.jhepr.2025.101624

N/A

0DataRank · unranked

0 citations

Ana Verma, Vy H. Nguyen, Eric M. Przybyszewski, Jiunn Song, Allison J. Carroll +5 more